Related Experiment Videos
Auto-immune (lupoid) hepatitis: an entity in the spectrum of chronic active liver disease
1Centre for Molecular Biology and Medicine, Monash University, Clayton, Victoria, Australia.
Insights
Auto-immune hepatitis evolved from chronic active hepatitis (CAH) descriptions. Key markers include specific auto-antibodies and histological features, though further research is needed for definitive diagnosis.
Area of Science:
- Immunology
- Hepatology
- Autoimmune Diseases
Background:
- Auto-immune hepatitis (AIH) concept emerged from 'chronic active hepatitis' (CAH) in the 1950s.
- AIH is characterized by distinct clinical, histological, and serological features.
- Several CAH subtypes exist, necessitating precise diagnostic criteria.
Purpose of the Study:
- To delineate the evolution and diagnostic markers of auto-immune hepatitis.
- To highlight the role and limitations of auto-antibodies in AIH diagnosis.
- To identify future research directions for a more confident AIH entity acceptance.
Main Methods:
- Review of historical descriptions of chronic active hepatitis.
- Analysis of distinctive clinical and histological features of auto-immune CAH.
- Evaluation of serological markers, including auto-antibodies (ANA, SMA) and HLA phenotype.
Main Results:
- Distinctive markers for auto-immune CAH include negative HBsAg, female predominance, Northern European ethnicity, multisystem involvement, specific histology (periportal piecemeal necrosis, plasmacytosis), hypergammaglobulinaemia, HLA B8-DR3, and steroid responsiveness.
- Auto-antibodies (ANA, SMA) are significant but not absolute markers; standardization and interpretation challenges exist.
- Hepatocellular carcinoma is rare in AIH.
Conclusions:
- Auto-immune hepatitis is a recognized entity with specific, though not exclusive, diagnostic markers.
- Further research is required, including identification of liver-specific antigens and disease models, to solidify AIH as a distinct entity.
- Understanding immune-mediated liver damage is crucial for advancing AIH diagnosis and management.
Abstract:
The concept of auto-immune hepatitis as a disease entity evolved from the descriptions of 'chronic active hepatitis' (CAH) in the 1950s. Several types of CAH are distinguished by disease-specific features. The distinctive (but not exclusive) markers for auto-immune CAH include: a negative test for HBsAg; female; Northern European ethnic background; multisystem disease expression; histological CAH with large areas of periportal piecemeal necrosis and plasmacytosis; pronounced hypergammaglobulinaemia; serum auto-antibodies the HLA B8-DR3 phenotype; responsiveness to corticosteroid therapy; and rarity of supervening hepatocellular carcinoma. Much weight is attached to the serological marker auto-antibodies to nuclear or smooth muscle (actin) antigens (ANA, SMA). However, these auto-antibodies do not have an absolute association with auto-immune CAH: the serological reactions are not yet standardized; titres decrease with remission of disease; and other auto-antibodies mark variant forms of auto-immune hepatitis. A more confident acceptance of auto-immune hepatitis as an entity requires detection of a liver-specific antigen, a valid experimental disease model in animals, and a better understanding of immune-mediated damage to liver cells.